Choline

Prenatal Vitamin Supplements Market to grow by USD 237.81 million from 2022 to 2027; North America to account for 51% of market growth- Technavio

Retrieved on: 
Monday, January 15, 2024

NEW YORK, Jan. 15, 2024 /PRNewswire/ -- The prenatal vitamin supplements market is expected to grow by USD 237.81 million from 2022 to 2027.

Key Points: 
  • NEW YORK, Jan. 15, 2024 /PRNewswire/ -- The prenatal vitamin supplements market is expected to grow by USD 237.81 million from 2022 to 2027.
  • This report offers an up-to-date analysis of the current market scenario, the latest trends and drivers, and the overall market environment.
  • Detailed information on factors that will drive the growth of the prenatal vitamin supplements market between 2022 and 2027.
  • Growth of the prenatal vitamin supplements market across North America, Europe, Asia, and ROW
    Comprehensive analysis of factors that will challenge the growth of the prenatal vitamin supplements market players.

REVIVELE LAUNCHES COMPREHENSIVE WOMEN'S SUPPLEMENT SYSTEM

Retrieved on: 
Monday, October 23, 2023

MIAMI, Oct. 23, 2023 /PRNewswire/ -- Revivele, the pharmacist-founded healthcare company empowering women to take control of their own health, has launched Essentials by Revivele, a comprehensive, easy-to-use supplement system tailored specifically to help improve and support women's overall health and longevity, especially as they enter their perimenopausal and post-menopausal years.

Key Points: 
  • Essentials by Revivele Takes the Guesswork out of Women's Supplementation with a System Designed to Support Cognitive Function, Balance Hormones, and Help Prevent Disease
    MIAMI, Oct. 23, 2023 /PRNewswire/ -- Revivele , the pharmacist-founded healthcare company empowering women to take control of their own health, has launched Essentials by Revivele , a comprehensive, easy-to-use supplement system tailored specifically to help improve and support women's overall health and longevity, especially as they enter their perimenopausal and post-menopausal years.
  • This strategic supplement system is also aimed at reducing the risk of chronic diseases like Alzheimer's, which affects twice as many women as men worldwide.
  • The Essentials by Revivele system is comprised of six daily products carefully formulated to work in harmony and be taken throughout the day.
  • For more information about Revivele and Dr. Desai, visit Revivele.com , or check out @Revivele.Inc on Instagram, Revivele.Inc on Facebook, and Revivele on LinkedIn.

UPDATE | Advanced imaging reveals altered brain chemistry of babies with congenital heart disease

Retrieved on: 
Monday, October 9, 2023

They found:

Key Points: 
  • They found:
    Those with CHD had higher levels of choline and lower levels of N-Acetyl aspartate-to-choline ratios compared to healthy babies, potentially representing disrupted brain development.
  • Babies with more complex CHD also had higher levels of cerebral lactate compared to babies with two ventricle CHD.
  • These critical heart defects generally require babies to undergo heart surgery not long after birth.
  • , chief of the Advanced Technologies and Surgery Branch in the Division of Cardiovascular Sciences at the National Heart, Lung and Blood Institute.

Advanced imaging reveals altered brain chemistry of babies with congenital heart disease

Retrieved on: 
Monday, October 9, 2023

They found:

Key Points: 
  • They found:
    Those with CHD had higher levels of choline and lower levels of N-Acetyl aspartate-to-choline ratios compared to healthy babies, potentially representing disrupted brain development.
  • Babies with more complex CHD also had higher levels of cerebral lactate compared to babies with two ventricle CHD.
  • These critical heart defects generally require babies to undergo heart surgery not long after birth.
  • , chief of the Advanced Technologies and Surgery Branch in the Division of Cardiovascular Sciences at the National Heart, Lung and Blood Institute.

Meati Foods™ Joins Snacking Revolution with Animal-Free, Shelf-Stable Jerky

Retrieved on: 
Tuesday, October 10, 2023

Meati Foods ™, creator of delectable, animal-free products crafted from the company's patented, whole-food MushroomRoot™, today introduced eat meati™ jerky, a shelf-stable snack series available for shipment direct to consumers’ doorsteps.

Key Points: 
  • Meati Foods ™, creator of delectable, animal-free products crafted from the company's patented, whole-food MushroomRoot™, today introduced eat meati™ jerky, a shelf-stable snack series available for shipment direct to consumers’ doorsteps.
  • “We’re excited to provide a snacking solution that provides superior nutrition and incredible flavor in meati jerky and can’t wait for people to try it.
  • Meati jerky is available in the online meati Marketplace at a price of $39 direct-to-doorstep, including shipping, for three different flavor pouches, each holding 2.2 oz or two servings.
  • While the jerky is currently available only direct-to-consumer, the company plans to take learnings from this initial launch into consideration for future commercialization planning.

Exploration at the 5th NYO3 NO-AGE/AD Meeting and the First Launch of New Anti-Aging Nutrition Co-Developed by NYO3 and NO-AGE

Retrieved on: 
Tuesday, September 26, 2023

On September 18-19 (Norwegian time), the 5th NYO3 NO-AGE/AD Meeting was successfully held at the University of Oslo, Norway.

Key Points: 
  • On September 18-19 (Norwegian time), the 5th NYO3 NO-AGE/AD Meeting was successfully held at the University of Oslo, Norway.
  • With deep awareness of the importance of anti-aging for human health, Norwegian high-end dietary supplement brand NYO3 shared the latest research on krill oil, an anti-aging nutrition, about its promotion of neuronal health by inhibiting senescence markers at the meeting.
  • NYO3 brought a new anti-aging nutrition into view.
  • The 5th NYO3 NO-AGE/AD Meeting has built a pioneering force in the field of anti-aging and health nutrition, and also provided a new reflection of the world’s cutting-edge scientific research achievements on promoting industry development.

Yumi Launches into Whole Foods Nationwide this Fall

Retrieved on: 
Tuesday, September 26, 2023

LOS ANGELES, Sept. 26, 2023 /PRNewswire/ -- Functional kids nutrition brand Yumi is expanding its retail footprint by introducing its popular line of organic, nutrient dense snacks to Whole Foods this fall. The leading children's nutrition and food sciences company will offer nutrition-first, clean-certified snacks for toddlers and young children at Whole Foods locations nationwide. This expansion features their top-selling, Rice-Free, Organic Meltable Puffs and Superfood Veggie Organic Bars, including a "Mango & Kale" flavor that will be available exclusively at Whole Foods.

Key Points: 
  • LOS ANGELES, Sept. 26, 2023 /PRNewswire/ -- Functional kids nutrition brand Yumi is expanding its retail footprint by introducing its popular line of organic, nutrient dense snacks to Whole Foods this fall.
  • The leading children's nutrition and food sciences company will offer nutrition-first, clean-certified snacks for toddlers and young children at Whole Foods locations nationwide.
  • This expansion features their top-selling, Rice-Free, Organic Meltable Puffs and Superfood Veggie Organic Bars, including a "Mango & Kale" flavor that will be available exclusively at Whole Foods.
  • The brand, which launched its retail business in 2021 with Target, also expanded into Sprouts nationwide earlier this year.

a2 Platinum® Infant Formula Launches in U.S. - Made with Fresh a2 Milk®

Retrieved on: 
Wednesday, September 13, 2023

BOULDER, Colo., Sept. 13, 2023 /PRNewswire/ -- The a2 Milk Company today announced that its highly regarded a2 Platinum® Premium Infant Formula will hit store shelves in the U.S. for the first time this month with initial distribution in nearly 250 Meijer stores (available now), and 50 Wegman's stores (available 9/18). It can also be purchased online at a2nutrition.com and is soon to be available on Amazon.com.

Key Points: 
  • a2 Platinum® has been sold internationally for more than a decade and is one of the top-10 Infant Formula brands globally with annual retail sales of over US $1 billion.
  • The product is made with fresh a2 Milk® sourced from carefully selected dairy farmers in New Zealand's pure and natural South Island.
  • Produced nearby at modern, state-of-the-art manufacturing facilities close to Christchurch, The a2 Milk Company prides itself on its food safety and quality standards with zero recalls.
  • With a2 Platinum®, the company is now bringing an infant formula made with a2 Milk® to U.S. parents and caregivers seeking alternatives for feeding newborns from 0-12 months.

LATEST EFSA Approval: Choline Acknowledged for the first time as Essential Nutrient for Normal Liver Function of the Foetus and Exclusively Breastfed Infants1

Retrieved on: 
Wednesday, August 30, 2023

Choline is involved in the structure of cell membranes, cell signaling, neurotransmitter synthesis and contributes as phosphatidylcholine to a normal lipid metabolism and transport from the liver to extrahepatic tissues.

Key Points: 
  • Choline is involved in the structure of cell membranes, cell signaling, neurotransmitter synthesis and contributes as phosphatidylcholine to a normal lipid metabolism and transport from the liver to extrahepatic tissues.
  • Always on the Pulse of Science, Femibion® identified Choline as the next essential nutrient that could be crucial from the first moment of life in prenatal care.
  • That’s why today our Femibion portfolio contains Choline with Femibion® Phase 1 (early pregnancy), Femibion® Phase 2 (pregnancy) and Femibion® Phase 3 (breastfeeding).
  • Low maternal folate level is one of the risk factors in the development of neural tube defects in the developing foetus.

Protara Therapeutics Announces Second Quarter 2023 Financial Results and Business Update

Retrieved on: 
Thursday, August 3, 2023

Research and development expenses for the second quarter of 2023 increased to $7.2 million from $3.1 million during the second quarter of 2022, primarily reflecting an increase in expenses related to clinical and non-clinical trial activities for TARA-002.

Key Points: 
  • Research and development expenses for the second quarter of 2023 increased to $7.2 million from $3.1 million during the second quarter of 2022, primarily reflecting an increase in expenses related to clinical and non-clinical trial activities for TARA-002.
  • General and administrative expenses for the second quarter of 2023 decreased to $4.9 million from $5.6 million for the prior year period, primarily due to lower employee related expenses.
  • For the second quarter of 2023, Protara reported a net loss of $11.3 million, or $1.00 per share, compared with a net loss of $8.5 million, or $0.76 per share, for the same period in 2022.
  • Net loss for the second quarter of 2023 included approximately $1.6 million of stock-based compensation expenses.